Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016

Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted o... Mehr ...

Volltext
Verfasser: Rutten, Karlijn H G
Raymakers, Reinier A P
Hazenberg, Bouke P C
Nienhuis, Hans L A
Vellenga, Edo
Minnema, Monique C
Dokumenttyp: Artikel
Erscheinungsdatum: 2018
Reihe/Periodikum: Rutten , K H G , Raymakers , R A P , Hazenberg , B P C , Nienhuis , H L A , Vellenga , E & Minnema , M C 2018 , ' Haematological response and overall survival in two consecutive Dutch patient cohorts with AL amyloidosis diagnosed between 2008 and 2016 ' , Amyloid , vol. 25 , no. 4 , pp. 227-233 . https://doi.org/10.1080/13506129.2018.1536043
Schlagwörter: AL amyloidosis / survival / prognosis / time trend / LIGHT-CHAIN AMYLOIDOSIS / STEM-CELL TRANSPLANTATION / IMPROVED OUTCOMES / STAGING SYSTEM / MANAGEMENT / MELPHALAN
Sprache: Englisch
Permalink: https://search.fid-benelux.de/Record/base-29445269
Datenquelle: BASE; Originalkatalog
Powered By: BASE
Link(s) : https://hdl.handle.net/11370/f924cbc9-07b7-493d-95a8-1ef073fbfcff

Background: Although survival has improved in recent decades, the short-term prognosis of patients with immunoglobulin light chain (AL) amyloidosis remains grim. We aimed to assess overall survival (OS) of AL amyloidosis patients by comparing cohorts in two consecutive time periods.Methods: Data were collected and compared on 126 patients from two tertiary referral centres in The Netherlands during the time periods 2008-2012 and 2013-2016.Results: There was a non-significant trend to improved 6-month OS in the last cohort (78% vs. 67%, p=.216, crude odds ratio 1.66, 95%CI 0.74-3.70, adjusted odds ratio 2.22, 95%CI 0.88-5.56). Patients in this cohort had higher Mayo risk scores (stage III 40% vs. 24%, p